Avadel CNS Pharmaceuticals, LLC

Complaint pleads infringement of US 10,736,866 arising from Granules' ANDA/Paragraph IV certification. The narrative also mentions the '062 patent, but it cannot be decoded to a full patent number from the narrative.

DrugPatentWatch lists the '400 patent in this Avadel matter; the exact case number and whether the '400 patent was actually asserted could not be independently confirmed. It is listed as pending/ongoing.

APA challenge to FDA's requirement that Avadel certify against U.S. 8,731,963 (REMS patent). Jazz Pharmaceuticals intervened on July 28, 2022, to defend the FDA decision. The D.D.C. denied Avadel's requested relief, holding Avadel had an adequate remedy at law via its delisting counterclaim in the Delaware action.

Avadel's action against Jazz alleging breach of confidentiality agreements, trade-secret misappropriation, correction of inventorship under 35 U.S.C. § 256, and antitrust counterclaims, relating to subject matter Avadel alleges Jazz copied into its patents including the '488 patent. Jazz's motion to dismiss and motions to stay were denied. Resolved by the October 2025 global settlement and dismissed with prejudice.

Avadel's affirmative trade-secrets and inventorship action; Avadel alleged Jazz used confidential information and sought correction of inventorship of certain Jazz patents, including the '782 patent. Dismissed with prejudice on October 27, 2025 pursuant to settlement.

Declaratory-judgment action listing the '219 patent among patents in the case, including 10,272,062; 10,736,866; 10,952,986; 7,851,506; and 8,731,963. Final disposition not confirmed.

Avadel-side Delaware action in which Flamel/Avadel asserted their modified-release GHB patent family, including U.S. 10,272,062 and 10,736,866 (parents of the '986 patent) and U.S. 10,952,986, against Jazz. The case was consolidated and dismissed by order on 2025-10-27 as part of the settlement.

Avadel CNS Pharmaceuticals, LLC filed a case against Jazz Pharmaceuticals, Inc. in the District of Delaware. It was part of the global Jazz-Avadel dispute and was settled in October 2025, with District of Delaware cases terminated 2025-10-27.

Consolidated Federal Circuit appeal from D. Del. Nos. 1:21-cv-00691-GBW, 1:21-cv-01138-GBW, and 1:21-cv-01594-GBW concerning the permanent injunction in the '782 patent dispute. The Federal Circuit reversed-in-part, vacated-in-part, and remanded on May 6, 2025.